化学界"燃爆现场"——ACS Fall 2025 (美国化学会秋季年会) 在美国华盛顿举行！速来浏览科研新鲜事儿~

在 Medicinal Chemistry 的 First-Time Disclosures 专场里，13 位科研先锋首次公开了「潜力爆棚」的新分子结构，覆盖寄生虫病、心脏病、炎症、帕金森影像剂、肿瘤等诸多领域。

不只是小分子，还有 molecular glue、stapled peptide 乃至放射示踪探针，多种创新药物形态齐登台，实在太燃了！

Section.01
精选亮点抢先看

 
Section.02
小结

ACS Fall 2025 的新分子披露，不仅展示了药物化学前沿的多样性与创造力，也为临床转化打开了新的大门。未来几年，这些“初登场”的分子，或许会成为改变疾病治疗格局的关键力量。

[1] H Rachel Lagiakos, et al. Discovery of IID432: A highly efficacious and safe cyanotriazole inhibitor of Trypanosoma cruzi topoisomerase II for short-duration curative treatment of Chagas disease. ACS. 2025 Aug 20.
[2] Thomas Cummins, et al. Discovery of BMS-986470, a first-in-class molecular glue dual degrader of zinc finger and BTB domain containing 7A (ZBTB7A) and widely interspaced zinc finger protein (WIZ) for the treatment of treatment of Sickle Cell Disease. ACS. 2025 Aug 20.
[3] Leena Patel, et al. Discovery of GS-1427: A potent and selective, oral α4β7 inhibitor for the treatment of inflammatory bowel disease. ACS. 2025 Aug 20.
[4] David Ebner, et al. Development of colon-targeted pan-SIK inhibitor PF-07899895 for the treatment of IBD. ACS. 2025 Aug 20.
[5] Karolina Nilsson, et al. AZD0233: An oral CX3CR1 antagonist in development for the treatment of cardiovascular disease. ACS. 2025 Aug 20.
[6] Michael Green, et al. Discovery of clinical candidate PF-07293893: A novel and selective AMPK gamma 3 activator for the treatment of heart failure. ACS. 2025 Aug 20.
[7] Helen Mitchell, et al. Discovery of [11C]MK-7337, a novel high-affinity alpha-synuclein PET ligand for imaging in idiopathic Parkinson’s disease patients. ACS. 2025 Aug 20.
[8] Jennifer Riggs, et al. Discovery of a first-in-class molecular glue degrader of WEE1 kinase, BMS-986463, for the treatment of advanced malignant solid tumors. ACS. 2025 Aug 20.
[9] Robert Hudkins, et al. TYRA-200: Next generation inhibitor designed to potently target FGFR2 alterations and resistance mutations. ACS. 2025 Aug 20.
[10] Meredeth McGowan, et al. Discovery of MOMA-341, a chemically distinct, potent and selective covalent inhibitor of Werner Syndrome Helicase (WRN). ACS. 2025 Aug 20.
[11] Krista Goodman, et al. Discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of Microsatellite Stable (MSS) Colorectal Carcinoma. ACS. 2025 Aug 20.
[12] Brian White, et al. Discovery of FOG-001, a clinical stage Helicon inhibitor of the beta-catenin/TCF4 interaction. ACS. 2025 Aug 20.
[13] Chunhui Huang, et al. ETN029: Discovery and development of a DLL3-targeting radioligand therapy for the treatment of SCLC and beyond. ACS. 2025 Aug 20.